Individualized therapy for pericarditis

Massimo Imazio, Antonio Brucato, Rita Trinchero, David Spodick, Yehuda Adler

Research output: Contribution to journalReview articlepeer-review


The treatment of pericarditis remains largely empirical owing to a relative lack of randomized, controlled trials; nevertheless, a number of observational studies and the first randomized trials are moving the management of pericardial diseases on the road to evidence-based medicine. Moreover, emerging data suggest that treatment can be tailored to the specific patient and, although the optimal length of treatment is not clearly established, some recommendations can be formulated to guide management and follow-up. Aspirin or a NSAID at medium-to-high dosages are the mainstay of treatment (e.g., aspirin 2-4 g/day, ibuprofen 1200-1800 mg/day, indomethacin 75-150 mg/day). Corticosteroid use should be restricted, and low-to-medium doses (i.e., prednisone 0.2-0.5 mg/kg/day) should be preferred. Colchicine 0.5-1.2 mg/day is effective for reducing recurrences.

Original languageEnglish
Pages (from-to)965-975
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Issue number8
StatePublished - Aug 2009
Externally publishedYes


  • Aspirin
  • Colchicine
  • Corticosteroid
  • Pericarditis
  • Treatment


Dive into the research topics of 'Individualized therapy for pericarditis'. Together they form a unique fingerprint.

Cite this